Takashi Nakada

ORCID: 0009-0000-6846-8820 · 8 papers in corpus
preprint 2024
Figure S3 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338022.v1

CDH6 expression in cell lines and cytotoxic activity in vitro.

preprint 2024
Figure S3 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338022

CDH6 expression in cell lines and cytotoxic activity in vitro.

preprint 2024
Figure S4 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338019

ADCC and CDC activity of R-DXd.

preprint 2024
Figure S4 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338019.v1

ADCC and CDC activity of R-DXd.

preprint 2024
Figure S5 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338016

The concentration of R-DXd and total Ab in monkey plasma.

preprint 2024
Figure S5 from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338016.v1

The concentration of R-DXd and total Ab in monkey plasma.

preprint 2024
Table S3. from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338007.v1

Concentration of sCDH6 in cell culture supernatant.

preprint 2024
Table S3. from Raludotatug Deruxtecan, a CDH6-Targeting Antibody–Drug Conjugate with a DNA Topoisomerase I Inhibitor DXd, Is Efficacious in Human Ovarian and Kidney Cancer Models
·doi:10.1158/1535-7163.25338007

Concentration of sCDH6 in cell culture supernatant.